Innate Pharma (IPHA) EBT Margin (2019 - 2025)
Innate Pharma (IPHA) posted quarterly EBT Margin of 1764.51% for Q4 2025, down 137257.0% year-on-year from N/an in Q4 2024, and down 350.2% on a QoQ basis from 391.94% in Q4 2024.
Innate Pharma (IPHA) EBT Margin (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported EBT Margin for 7 consecutive years, with 1764.51% the latest figure, recorded in Q4 2025.
- Quarterly EBT Margin fell 137257.0% year-over-year to 1764.51% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 191.47% (down 11368.0% YoY) and the FY2025 annual result came in at 546.11%, down 30024.0% from the prior year.
- EBT Margin eased to 1764.51% in Q4 2025 per IPHA's latest filing, from 391.94% in the prior quarter.
- Over the last five years, EBT Margin for IPHA reached as high as 0.03% in Q4 2022 and fell as low as 1764.51% in Q4 2025.
- A 5-year average of 410.16% and a median of 298.61% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin surged 39482 bps — and 2025, when it tumbled 137257 bps.
- Year by year, EBT Margin stood at 394.86% in 2021, then soared by 100 bps to 0.03% in 2022, then sank by 43927 bps to 14.59% in 2023, then sank by 2587 bps to 391.94% in 2024, then tumbled by 350 bps to 1764.51% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 1764.51%, 391.94%, and 298.61% for Q4 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -1,764.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,764.51% |
| Dec 31, 2024 | -391.94% |
| Jun 30, 2024 | -298.61% |
| Dec 31, 2023 | -14.59% |
| Jun 30, 2023 | -6.59% |
| Dec 31, 2022 | -0.03% |
| Dec 31, 2021 | -394.86% |
| Dec 31, 2020 | -1.48% |
| Dec 31, 2019 | -30.10% |